• n  the property of eliciting an immune response

News & Articles

• Vaxart’s Groundbreaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans
  Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced positive safety and immunogenicity data from phase I clinical studies with its oral H1N1 seasonal influenza vaccine candidate.
  June 19, 2013 - Business Wire via Yahoo! Finance

Quotes

• Ellen Vitetta in EurekAlert (press release)
  This is a safety and immunogenicity trial,said Dr. Ellen Vitetta, director of the Cancer Immunobiology Center at UT Southwestern. "To test the immune response induced by the vaccine, the sera (blood products) from our injected human...